San Antonio, Texas USA (UroToday.com) Scott Regenbogen, University of Michigan, discussed colon cancer surveillance in comparison to that used in urologic oncology.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Despite level one evidence in colorectal surgery there are limited risk stratification with infinite variations in surveillance modalities with evolving technology which makes guideline recommendations for surveillance recommendations challenging. Given the numerous risk factors associated with colorectal cancer and various imaging modalities it is increasingly difficult to provide ‘high level’ evidence to support the optimal surveillance strategy. Unfortunately, there have been reported no survival difference among those having more intense surveillance versus those that either have limited to no surveillance. In the OPRA trial assessing colorectal surveillance the results regarding surveillance were similar. Thus, while urologists may feel uncertain regarding surveillance strategies among urologic cancers we are not alone as illustrated by our colorectal colleagues.
Presented By: Scott Regenbogen, University of Michigan
Written By: Stephen B. Williams, MD and Ashish M. Kamat
17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA